Townsquare Capital LLC lessened its stake in Azenta, Inc. (NASDAQ:AZTA – Free Report) by 11.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 51,990 shares of the company’s stock after selling 7,052 shares during the period. Townsquare Capital LLC owned about 0.11% of Azenta worth $2,518,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in AZTA. Lazard Asset Management LLC bought a new stake in Azenta in the 1st quarter valued at $130,000. Wesbanco Bank Inc. raised its position in Azenta by 56.5% in the second quarter. Wesbanco Bank Inc. now owns 18,000 shares of the company’s stock worth $947,000 after purchasing an additional 6,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Azenta in the 2nd quarter valued at approximately $611,000. Raymond James & Associates lifted its position in shares of Azenta by 0.5% during the 2nd quarter. Raymond James & Associates now owns 110,948 shares of the company’s stock worth $5,838,000 after buying an additional 594 shares during the period. Finally, IMA Advisory Services Inc. acquired a new stake in Azenta in the 2nd quarter valued at $1,486,000. Institutional investors and hedge funds own 99.08% of the company’s stock.
Wall Street Analysts Forecast Growth
AZTA has been the subject of a number of analyst reports. Evercore ISI cut their price objective on Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Needham & Company LLC dropped their target price on shares of Azenta from $69.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $63.60.
Azenta Stock Performance
Azenta stock opened at $46.21 on Friday. Azenta, Inc. has a 52 week low of $38.82 and a 52 week high of $69.16. The firm has a market cap of $2.26 billion, a P/E ratio of -15.56 and a beta of 1.48. The business’s fifty day moving average is $44.95 and its two-hundred day moving average is $49.89.
Azenta (NASDAQ:AZTA – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.08. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The firm had revenue of $170.00 million for the quarter, compared to analyst estimates of $169.66 million. During the same quarter in the prior year, the firm earned $0.13 EPS. The company’s revenue was down 1.2% on a year-over-year basis. On average, equities research analysts predict that Azenta, Inc. will post 0.4 earnings per share for the current year.
Insider Activity at Azenta
In other Azenta news, CFO Herman Cueto sold 1,595 shares of the stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $43.68, for a total value of $69,669.60. Following the transaction, the chief financial officer now directly owns 24,604 shares in the company, valued at approximately $1,074,702.72. This trade represents a 6.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Marotta bought 12,717 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were purchased at an average price of $39.48 per share, with a total value of $502,067.16. Following the transaction, the chief executive officer now owns 99,612 shares of the company’s stock, valued at $3,932,681.76. The trade was a 14.63 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 3,018 shares of company stock valued at $126,689 over the last quarter. Corporate insiders own 1.77% of the company’s stock.
Azenta Profile
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Read More
- Five stocks we like better than Azenta
- Breakout Stocks: What They Are and How to Identify Them
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 11/25 – 11/29
- What is a Secondary Public Offering? What Investors Need to Know
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.